arrow
D

David Santamarı́a

csic-universidad de salamanca
H指数:30
被引数:5,010

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity

Varela-Vázquez, A.; Guitián-Caamaño, A.; Carpintero-Fernández, P.; Carneiro-Figueira, A.; Álvarez, V.; Varela-Eirín, M.; Calleja-Chuclá, T.; Bravo-López, S.B.; Vidal, A.; Sendón-Lago, J.; et al. Cx43通过降低DNA修复能力增强对BRAF/MEK抑制剂的反应。Nat. Commun. 2025, 16, 6168. [Google Scholar] [CrossRef] [PubMed]

2025-07-040
OAAI
Cell cycle duration determines oncogenic transformation capacity

细胞周期时长决定致癌转化能力

NATURE
IF48.5
2025-04-301
OA
Type I interferon signaling pathway enhances immune- checkpoint inhibition in KRAS mutant lung tumors

I型干扰素信号通路增强KRAS突变型肺肿瘤的免疫检查点抑制

2024-08-260
PRE
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF V600E lung adenocarcinoma
2024-08-011
OAAI
Reuniting philosophy and science to advance cancer research

将哲学与科学重新结合以推进癌症研究

2023-05-088
OA
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

KRAS/P53突变型肺腺癌中CDK4和RAF1失活后的肿瘤消退和耐药机制

2020-09-1016
OAAI
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma
2020-08-0618
OA